Rockville, MD. (January 20, 2023) – Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic cellular therapeutics conducted first in-person investigator meeting in San Diego focused on our Cryopreserved Platelet Product.
"Together, Cellphire and the Principal Investigators of the CRYPTICS trial reviewed the 30-yearhistory of cryopreserved platelets, ironed out paths to recruitment and shared site experiences. Important aspects of the CPP clinical development program were discussed with focus on key upcoming CPP clinical protocol updates,” said Anya Derbij, Vice President of Clinical Operations. “The energy, expertise, and professionalism of the investigators was inspirational.”
"This is an important milestone for the company on the road to achieving our mission of saving lives with our cellular therapeutics,” said Allan Alexander, Cellphire Therapeutics CMO. “We appreciate and thank our investigators, the study site teams, collaborators, federal funding agencies, and our clinical operations team for coming together to make new life-saving hemostatic treatments a reality.”
This meeting was attended by all 17 of the study sites (listed below). The Cellphire team is greatly appreciative of the sites that sent representatives to the meeting. 11 Principal Investigators (PI’s), 15 clinical research coordinators, and 12 blood bank representatives were able to participate.
Clinical Sites in attendance:
University of Oklahoma Health Sciences Center, University of Florida – Gainesville, University of Colorado, Thomas Jefferson University Hospital, Oregon Health & Science University, Maine Medical Center, Inova Health System, George Washington University Hospital, Johns Hopkins University, University of California San Francisco VA Medical Center, University of Virginia, University of Maryland School of Medicine, University of Alabama Hospital, Duke University, Ohio State University, Dartmouth-Hitchcock Medical Center, Abington Memorial
About Cellphire Therapeutics
Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation allogeneic cellular therapeutics. The company is applying its proprietary cell stabilization technology first to platelets, to develop lifesaving products. Its lead investigational product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technologies support a wide range of potential medical applications for Orphan populations to surgical, trauma, traumatic brain injury (TBI) and intercranial hemorrhage (ICH) unmet clinical needs, among other things. For more information, visit www.cellphire.com.
This work is supported by the US Army Medical Research and Development Command under Contract No. W81XWH20C0030. The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation."
Media and Investor Relations
Director, Business Operations